Heterodimeric antibodies that bind CD3 and tumor antigens
US11859011B2 · kind B2 · utility
0Cited by
129References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2021 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Feb 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to novel heterodimeric antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.